Juneko Elaine Grilley-Olson MD (She/Her)

Sarcoma

Associate Professor, Medicine, Duke School of Medicine

30 Duke Medicine CirDurham, NC 27710
Phone+1 919-668-2168

Dr. Grilley-Olson is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Grilley-Olson's full profile Already have an account?

Summary

Dr. Juneko Grilley-Olson is an oncologist in Durham, NC and is affiliated with Duke University. She received her medical degree from University of Wisconsin School of Medicine and Public Health and has been in practice 14 years. She specializes in sarcoma, and developmental therapeutics.

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2006 - 2009
Hennepin HealthcareResidency, Internal Medicine, 2003 - 2006
University of Wisconsin School of Medicine & Public HealthClass of 2003

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

GA State Medical License 2026 - 2028
TN State Medical License 2026 - 2028
MS State Medical License 2026 - 2027
NC State Medical License 2006 - 2027
AL State Medical License 2026 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
CMS Meaningful Use Stage 1 Certification WebCIS, UNC Health Care, 2012, 2014-2017

Clinical Trials

Everolimus Versus Placebo in Head and Neck Cancer
TERMINATED
PHASE2
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
COMPLETED
PHASE2
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy Start of enrollment: 2013 Oct 01
TERMINATED
PHASE2

Publications & Presentations

PubMed

Symptom management and transitioning to engagement with post-treatment care for adolescent and young adult cancer survivors (AYA STEPS): Study protocol.
Caroline S Dorfman, Sarah S Arthur, Rebecca A Shelby, Juliann M Stalls, Nicole A Arrato
Contemporary Clinical Trials. 2026-09-01
1 citations
All Hands on Deck: A Novel Collaborative Model for Care Provision in Young Adult Oncology.
Julie S W Childers, Jacob N Stein, Catherine Swift, Daniel Kleissler, Emily Haines
Journal of Adolescent and Young Adult Oncology. 2025-12-01
1 citations
Management of Desmoid Tumors.
Juneko E Grilley-Olson, Gina Sotolongo, William R Jeck, Charles Y Kim, Nicole Larrier
Current Oncology Reports. 2025-11-01

Lectures

SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018